Sign inJoin waitlistJoin the waitlist

Raid Aljumaily

Director of Clinical Trials Office · University of Oklahoma College of Medicine

Credentials: · · · · · ·

History

University of Oklahoma College of Medicine
Present

Hematology/OncologyTufts Medical Center
1996–1997
Hahnemann University Hospital -American Academic Health System
1993–1996
Baghdad University, College of Medicine
1989–1993

Research

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Nature Medicine · 2019 · 752 citations
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
The Lancet Oncology · 2018 · 469 citations
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
Annals of Oncology · 2019 · 142 citations

Manish Patel
7 papers
JI
Jeffrey Infante
5 papers
Michael Gordon
5 papers
Sami Ibrahimi
5 papers · 5 as a fellow
Sarbajit Mukherjee
5 papers · 5 as a fellow
Aung Naing
4 papers
KP
Kyriakos Papadopoulos
4 papers
Abdul Naqash
3 papers
AH
Annie Hung
3 papers · 1 as a fellow
Deborah Wong
3 papers
Howard Safran
3 papers
JB
Johanna Bendell
3 papers

Grants

Promoting Lead Academic Participating Sites (LAPS) Studies Accrual and Lung Cancer Screening in Oklahoma
National Cancer Institute · R50
Contact PI · $424.5K · University of Oklahoma Hlth Sciences Ctr
2025–2029
Stephenson Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $420.6K · University of Oklahoma Hlth Sciences Ctr
2018–2028

Clinical trials

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2021–2027
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Principal investigator · Completed · Phase 1, Phase 2
MedImmune LLC
2014–2020
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Study chair · Active not recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2024–2030
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028